<DOC>
	<DOCNO>NCT01332669</DOCNO>
	<brief_summary>In unresectable hepatocellular carcinoma , TACE use Lipiodol/anti cancer agent emulsion standard treatment report significantly well treatment randomize comparison study like Llovet , etc . conservative treatment . Recently , doctor transarterial chemoembolization drug-eluting bead , prove less side effect well efficacy conventional TACE use Lipiodol Precision V study Dr. Lammer , etc . But , could define improved survival rate expect . This study 's purpose evaluate treatment efficacy , survival rate safety TACE use drug elute bead compare conventional TACE use doxorubicin/Lipiodol emulsion unresectable hepatocellular carcinoma .</brief_summary>
	<brief_title>Drug-eluting Bead Hepatocellular Carcinoma</brief_title>
	<detailed_description>Comparison Between Drug-Eluting Bead v conventional TACE . Drug-eluting bead group : TACE use DC bead load Doxorubicin . Conventional TACE group : TACE use Doxorubicin/Lipiodol emulsion gelatin sponge/PVA particle . cTACE group choose concurrent match patient ( age , sex , tumor stage , Child-Pugh class match ) 5.7 Technically considerable aspect DC bead TACE group 1 . Planned dose doxorubicin . Each vial DC Bead ( 2 ml bead ) load 70-75 mg doxorubicin ( load dose , 35-37.5 mg doxorubicin / ml bead ) . - Early-stage HCC . As general rule , single treatment include plan dose 75 mg doxorubicin load one vial DC Bead . - Medium-sized ( less 8cm ) / multinodular HCC . As general rule , single treatment include plan dose 150 mg doxorubicin load two vial DC Bead . - In large tumor ( 8cm ) , even unilobar , separate treatment include two session 2-4 week apart recommend . - In bilobar tumor , hepatic lobe treat separate treatment session 2-4 week apart , absence complication require long time interval two session . Obtaining confirmation liver enzymes return baseline perform second treatment session recommend . 2 . Choice DC Bead size . Use 100-300μm bead recommend standard procedure . However , individual patient tumor characteristic , particularly identification arterio-venous shunting , take account safety treatment choice DC Bead size determine . - In case significant arterio-portal hepatic venous shunting , embolization shunt gelfoam pledgets recommend proceed DEBDOX . Confirmation shunt longer present must obtain DEBDOX safely perform . But , study excludes patient arterio-portal hepatic venous shunt . - In large tumor , hepatic arterial flow reach 'near stasis ' injection 2 vial 100-300 μm DC bead . The recommendation follow : 2 vial 100-300 μm DC bead best repeat 2 week later patient well clinically . 3 . DC Bead dilution . Mix load DC Bead non-ionic contrast medium . At least 5-10 ml non-ionic contrast use per 1 ml DC Bead ( i.e. , 10-20 ml require dilute one vial DC Bead ) prior injection . 4 . Catheter position . A superselective ( i.e. , segmental subsegmental ) approach use whenever possible use microcatheter . Use 3D / MPR obtain C-arm rotational angiography flat-panel detector system ( cone-beam CT ) recommend , available , improve accuracy identify tumor-feeding artery . Such imaging allows accurate target tumor . In addition , repeat cone beam CT perform successful delivery DC Bead confirm adequate target saturation tumor ( ) . - Segmental / subsegmental approach . Place microcatheter segmental / subsegmental vessel feed tumor distally possible - avoid wedge catheter avoid reflux along catheter shaft . Flow within artery must preserve . - Lobar approach . Place catheter selectively possible right leave hepatic artery . Pay attention identify origin cystic artery well arteries supply flow extra-hepatic organ right gastric artery , para-esophageal omental vessel among others . If identify , vessel must either embolized use coil avoid place catheter tip well beyond origin vessel . In addition , forward flow desire vessel must maintain inadvertent administration even DC Beads extra-hepatic vessel could dire consequence . 5 . Injection . The injection must slow . An injection rate 1 ml contrast agent - DC Bead suspension per minute recommend . Thus , take 10-20 minute infusion 1 vial DC bead . Care take avoid sedimentation bead syringe rotate syrinx use 3-way stopcock gently suspend bead solution . 6 . Embolisation endpoint . Injection continue `` near stasis '' observe artery directly feed tumor ( i.e. , contrast contrast column clear within 2-5 heart beat ) . At point , injection stop - regardless amount bead actually administer - avoid reflux embolic material . Once embolisation endpoint achieve , additional embolic material inject . If `` near stasis '' endpoint obtain injection schedule volume bead , additional embolization perform . This patient likely benefit second course image follow-up . 7. extrahepatic collateral vessel . In principle , DC bead use collateral arterial circulation ( inferior phrenic artery , internal mammary artery , intercostal artery ) , doctor bland embolization ( PVC particle , gelatin sponge ) base judgement . 8 . Repeated treatment . In principle , treatment method repeat every 2 - 3 month tumor progression observe . But , even tumor progression observe , treatment repeat tumor repression . If tumor leave , contrast enhancement CT MRI perform every 2- 3 month follow . 5.8 . Dose study Dose DC bead , anti cancer agent TACE dose decide tumor size . So , study set maximum dose . Drug-eluting bead group DC bead : 2 bottle DC bead absorbs 70-75mg per bottle . Doxorubicin load DC bead need do 1.5 hour use . The size DC bead 100-300 micrometer , use 2 bottle .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Patients confirm diagnosis HCC state Cirrhotic subject : Clinical diagnosis AASLD criterion Noncirrhotic subject : histological confirmation mandatory 2 . Patient HCC suitable radical therapy resection , liver transplantation percutaneous therapy patient indicated therapy contraindication patient reject treatment want TACE ( Indication hepatectomy , liver transplantation , local ablation decide doctor center ) 3 . Multinodular single nodular tumor 5cm , ( In case single nodule less 5cm , curative treatment contraindicate patient reject curative treatment ) 4 . Hypervascular lesion show contrast enhancement early stage contrast medium bolus injection CT MRI . 5 . At least one unidimensional lesion measurable accord Modified RECIST criterion CTscan MRI 6 . No invasion blood vessel ( hepatic portal , hepatic vein ) bile duct CT MR 7 . Eastern Cooperative Oncology Group performance status 0 1 8 . ChildPugh classification A B7 9 . Proper blood , liver , renal , heart function : testing result within 2 week registry study follow : white blood cell number : &gt; 3,000/mm2 platelet number : &gt; 5 x 104/mm3 blood bilirubin : &lt; 3.0 mg/dL ASL , ALT within 5 time normal range organ serum creatinine : &lt; 1.5 mg/dL hemoglobin : &gt; 8.0 g/dL 10 . Over 20 year old 11 . Expected survival 6 month 12 . Patients willing regular visit , laboratory test , radiological exam 13 . Prior write patient consent 1 . ECOG performance status 2 , ChildPugh class B8 2 . Diffuse HCC presence vascular biliary invasion extrahepatic spread . 3 . Vascular biliary invasion 4 . Extrahepatic metastasis ( Any lymph nod measure ≥ 10mm along short axis ) 5 . Tumor burden involve 50 % liver 6 . Patients previously treat anticancer therapy HCC except hepatic resection early recurrence within 1 year resection 7 . Liver cancer rupture 8 . History biliary tract repair endoscopic biliary tract treatment 9 . Clinically important refractory ascites pleural fluid 10 . Any contraindication hepatic embolization procedure Known hepatofugal blood flow Arteriovenous shunt Impaired clot test ( platelet count &lt; 5 x 104/mm3 , PTINR &gt; 2.0 ) 11 . Any contraindication doxorubicin administration 12 . Contrast medium allergy contraindicate angiography 13 . Acute active following disease Heart failure ca n't control , angina pectoris and/or arrhythmia diseases Myocardial infarction within last 6months , Renal failure Active infection ( virus infection accept ) Active hemorrhage digestive system Other malignant tumor history Hepatic coma acute mental disease 14 . Pregnant , nurse childbearing age woman men actively sexually available n't want ca n't contraception 15 . Safety concern base researcher 's judge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>chemoembolization</keyword>
	<keyword>drug elute bead</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Korea</keyword>
</DOC>